Abstract The X-linked inhibitor of apoptosis (XIAP) deficiency is a primary immunodeficiency characterized by Epstein-Barr virus (EBV)-driven hemophagocytic lymphohistiocytosis (HLH), splenomegaly, and colitis. Here, we present, for the first time, granulomatous hepatitis and granulomatous and lymphocytic interstitial lung disease (GLILD) as manifestations of XIAP deficiency. We report successful treatment of GLILD in XIAP deficiency with rituximab and azathioprine and discuss the role of XIAP deficiency in immune dysregulation.
Introduction
The X-linked inhibitor of apoptosis (XIAP) deficiency is a primary immunodeficiency first described in 2006 [1, 2] . Over 70 cases have since been reported [3] , affecting males although there are recent reports of random X-inactivation resulting in female disease [4] . The clinical phenotype includes Epstein-Barr virus (EBV)-driven hemophagocytic lymphohistiocytosis (HLH), Crohn's like IBD, and splenomegaly. Other features such as a partial HLH, dysgammaglobulinemia and recurring cytopenias frequently complicate this condition while uveitis, cutaneous abscesses, hepatitis, a coeliac-like enteropathy, and Giardia lamblia enteritis have been occasionally reported [5] . The disease usually presents in childhood but presentation in adulthood is also recognized. No correlation has been observed between genotype/functional studies and the clinical phenotype [5] . XIAP, encoded by the BIRC4 gene [1] , belongs to a family of inhibitors of apoptosis (IAP) which has potent antiapoptotic activity through the inactivation of caspases [6] . Additional functions include signal transduction through the nucleotide-binding oligomerisation domain containing 2 (NOD2) receptor and subsequent activation of mitogenactivated protein kinase (MAPK) and nuclear factor kappa B (NFkB) pathways [7, 8] . This pro-inflammatory function of XIAP is curtailed through its negative regulatory role on the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome. Additional roles in the function of Dectin-1 and regulation of tumor necrosis factor (TNF) receptor 1 signaling are reported [3] .
Granulomatous and lymphocytic interstitial lung disease (GLILD), as a discrete histopathological entity, was first described in 2004 [9] . The hallmarks of this condition are granulomatous and lymphoproliferative changes (lymphocytic interstitial pneumonitis, follicular bronchitis, and/or lymphoid hyperplasia) on lung biopsy. GLILD has been most frequently described as a complication of CVID but has been reported with other PIDs including LRBA deficiency [10] , CTLA4 haploinsufficiency [11] , hypomorphic RAG1 mutations [12] and Kabuki syndrome [13] . The pathophysiology of GLILD is incompletely understood but treatment is directed against infiltrating T and B lymphocytes. Combination rituximab and azathioprine has been used in GLILD with reported improvements in pulmonary function (FEV 1.0 and FVC) and CT appearances [14] .
Here, we report the first case of XIAP deficiency complicated by granulomatous hepatitis and GLILD, expanding the clinical phenotype of XIAP deficiency.
Clinical Case
A male patient (#3) [15] was diagnosed aged 4 with EBV primary infection presenting with fever, tonsillitis, cervical lymphadenopathy, and hepatosplenomegaly. He had microcytic anemia and detectable EBV IgM. A bone marrow aspirate was reported as Breactive.^Computed tomography (CT) of the chest, abdomen, and pelvis did not demonstrate additional pathology. IgG, IgA, and IgM were normal. The patient recovered uneventfully.
Aged 16, the patient presented with a 3-month history of malaise and fever. Massive splenomegaly and firm jugulodigastric and inguinal lymph nodes were palpable. Blood results are available (Table 1) . CT imaging showed widespread mediastinal and abdominal lymphadenopathy, massive splenomegaly, and patchy areas of opacification throughout both lung fields. Plasma cells were not identified on bone marrow biopsy. There was no evidence of HLH. Lymph node histology confirmed reactive hyperplasia and prominent lymphoid follicles with large germinal centers. Immunohistochemical stains suggested reactive hyperplasia. A few small collections of histiocytes were seen but there were no granulomas. Hemophagocytosis was not identified. Mycobacterial stains and cultures were negative. EBV was not detectable in tissue sections or peripheral blood. SLAMassociated protein (SAP) expression was abnormal by immunoblot. Symptoms resolved spontaneously over 6 weeks with resolution of cytopenias and lymphadenopathy. Intravenous immunoglobulin replacement therapy was commenced, and arrangements were made for assessment in a national hematopoietic stem cell transplant center. Lymphocyte phenotyping showed almost complete absence of class-switched memory B cells, elevated transitional B cells (6.9 % reference 0.6-3.4 %), and mild increase in CD21 lo CD38 lo B cells (7.8 % reference 0.9-7.6 %). Repeat SAP expression by flow cytometry was normal, and no mutations were found in the SH2D1A gene. XIAP protein expression was reduced and sequencing of XIAP exons 1 to 7 showed a novel missense mutation in exon 2 (c.497G→A. p.Arg166Lys variant) (Fig. 1) . The same mutation and reduced XIAP expression was identified in two healthy brothers (aged 21 and 14; #4 and 5). The significance of the mutation was therefore uncertain. Immunoglobulins G, A, and M were within normal limits for both brothers; lymphocyte phenotyping showed reduced NK cells (Table 1) . At age 19 years, another episode of presumed Bpartialĥ emophagocytic lymphohistiocytosis (HLH) occurred. Corticosteroid therapy (Prednisolone 30 mg) improved the pyrexia, weight loss, and platelet counts but had no impact on splenomegaly. Liver function tests deteriorated over several months, and granulomatous inflammation with very mild fibrosis was found at biopsy (Fig. 2) . Corticosteroid dose was slowly tapered, and sirolimus was introduced but this had no effect on hematological or biochemical parameters or splenic diameter. Another Bpartial^HLH episode occurred 23 months later and responded similarly to oral prednisolone treatment. Hemophagocytosis was present on a bone marrow aspirate without evidence of EBV (Fig. 2) . Progressive cough and dyspnoea were reported over several months, and CT imaging (Fig. 3) revealed progressive interstitial changes and multiple nodular opacities, pronounced mediastinal lymphadenopathy, more marked in the lower lung zones. Pulmonary function testing (PFT) confirmed deteriorating lung function ( Table 2) . A thoracoscopic lung biopsy identified a non- necrotizing granulomatous pneumonitis, cellular and follicular bronchiolitis, and moderate areas of acute and fibrosing organizing pneumonia consistent with GLILD (Fig. 4) . There was a predominantly B cell chronic mononuclear infiltrate in lung biopsy tissue. Routine tissue culture, staining for HHV8, EBV, and CMV, and 16S real-time PCR testing were all negative. Combination chemotherapy with rituximab (375 mg/m 2 BSA × 4 doses) and azathioprine (2 mg/kg) led to a sustained improvement in pulmonary function and CT appearances while splenomegaly remained unchanged.
Methods

XIAP Expression
Intracellular XIAP expression was assessed by flow cytometry as described previously [16] using purified anti-XIAP IgG1.
Activation-Induced Cell Death
Activation-induced cell death (AICD) was performed on day 8, and PHA/IL-2 blasts were incubated with medium or platebound anti-CD3 or different concentrations (10, 25, 50 , and 100 ng) of Fas ligand (FasL) for 24 h, stained with annexin V (AV) and propidium iodide (PI), and analyzed by flow cytometry. The percentage of surviving cells was quantified: % AV-PI negative cells after incubation with anti-CD3 divided through % AV-PI negative cells after incubation with medium × 100.
Functional L18-MDP Assay
As described previously [15] , PBMCs were isolated and incubated in (a) medium alone or (b) in medium supplemented with lapidated muramyl dipeptide (L18-MDP) or (c) lipopolysaccharide (LPS). After staining with mAbs against CD14 and HLA-DR, the cells were fixed, permeabilized, and stained for TNFα, and results are acquired by flow cytometry.
Results
AICD studies failed to show increased apoptosis of activated T cells after re-stimulation with CD3/FasL in the patient or any family member (data not shown). Production of TNFα from monocytes using a NOD2-specific ligand (muramyl dipeptide) was absent in patient #3 and both brothers (#4 and #5) while normal for their mother (#2). Monocyte production of TNFα in response to lipopolysaccharide was normal (Fig. 5) . Given the history of HLH, the mutation in XIAP, and the functional assay results, the diagnosis of XIAP deficiency for #3 was confirmed, complicated by GLILD and The patient, now 23, continues to be considered for allogeneic hematopoietic stem cell transplantation (HSCT). A fully matched HLA sister (#6) is available.
Discussion
This is the first reported case of granulomatous hepatitis and GLILD occurring in XIAP deficiency. Furthermore, we demonstrate the success of combination chemotherapy with rituximab and azathioprine in this context. Neither rituximab/azathioprine nor sirolimus alone was effective in reducing splenomegaly, despite their utility in reducing splenomegaly in CVID and autoimmune lymphoproliferative syndrome (ALPS) [14, 17] . It is hoped that optimization of pulmonary function will enhance preparation for HSCT.
The patient and his clinical phenotype have been partially reported previously [15] . The near normal expression of XIAP Chronic mononuclear inflammation comprise mainly B lymphocytes (>75 %). This is highlighted by immunohistochemistry for CD20, which shows an intense and diffuse staining in B cell lymphocytes suggests a hypomorphic mutation, which could explain the normal AICD study, as there is sufficient residual expression to inhibit apoptosis in vitro. Two asymptomatic brothers similarly had near normal expression of XIAP and normal AICD studies while all three brothers had defective production of TNFα following stimulation with a NOD2-specific ligand. We speculate that there must be additional unknown environmental and/or genetic factors which influence the phenotypic expression of disease in this condition. Normal apoptosis studies do not exclude XIAP deficiency and therefore limit their clinical utility in this disease [5] . The roles of XIAP in signal transduction through NOD1/2 and in regulation of inflammasomes continue to be elucidated [3] but the failure of effective pathogen sensing coupled with defective inhibitory pathways of inflammasome control might explain some of the inflammation in this condition. It is of note that the inflammation seen in Crohn's disease is associated with aberrant signaling through NOD2 [18, 19] , and the defective NOD2 signaling seen in this case may implicate this pathway as important in the pathophysiology of GLILD and granulomatous hepatitis. This case highlights a potential broadening of the clinical phenotype of XIAP deficiency and the importance and complexity of molecular case definition. It is important to consider the possibility of GLILD and granulomatous hepatitis in XIAP deficiency and indeed the possibility of XIAP deficiency in Batypical^or severe CVID.
